| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Taysha Gene Therapies Inc (NASDAQ: TSHA)
TSHA Technical Analysis
5
| As on 9th Jun 2023 TSHA STOCK Price closed @ 0.86 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.92 & Strong Sell for SHORT-TERM with Stoploss of 9.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TSHASTOCK Price
| Open | 0.84 | Change | Price | % |
| High | 0.87 | 1 Day | 0.02 | 2.38 |
| Low | 0.83 | 1 Week | 0.16 | 22.86 |
| Close | 0.86 | 1 Month | 0.22 | 34.38 |
| Volume | 108880 | 1 Year | -14.16 | -94.27 |
| 52 Week High 15.02 | 52 Week Low 0.64 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TSHA Daily Charts |
TSHA Intraday Charts |
Whats New @ Bazaartrend |
TSHA Free Analysis |
|
|
TSHA Important Levels Intraday
| RESISTANCE | 0.94 |
| RESISTANCE | 0.91 |
| RESISTANCE | 0.90 |
| RESISTANCE | 0.88 |
| SUPPORT | 0.84 |
| SUPPORT | 0.82 |
| SUPPORT | 0.81 |
| SUPPORT | 0.78 |
TSHA Forecast May 2024
| 4th UP Forecast | 10.71 |
| 3rd UP Forecast | 7.55 |
| 2nd UP Forecast | 5.6 |
| 1st UP Forecast | 3.64 |
| 1st DOWN Forecast | -1.92 |
| 2nd DOWN Forecast | -3.88 |
| 3rd DOWN Forecast | -5.83 |
| 4th DOWN Forecast | -8.99 |
TSHA Weekly Forecast
| 4th UP Forecast | 5.60 |
| 3rd UP Forecast | 4.08 |
| 2nd UP Forecast | 3.14 |
| 1st UP Forecast | 2.20 |
| 1st DOWN Forecast | -0.48 |
| 2nd DOWN Forecast | -1.42 |
| 3rd DOWN Forecast | -2.36 |
| 4th DOWN Forecast | -3.88 |
TSHA Forecast2024
| 4th UP Forecast | 28.42 |
| 3rd UP Forecast | 19.58 |
| 2nd UP Forecast | 14.12 |
| 1st UP Forecast | 8.65 |
| 1st DOWN Forecast | -6.93 |
| 2nd DOWN Forecast | -12.4 |
| 3rd DOWN Forecast | -17.86 |
| 4th DOWN Forecast | -26.7 |
Taysha Gene Therapies Inc ( NASDAQ USA Symbol : TSHA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TSHA Business Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas. Address: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service